Research programme: antibacterials - Deinobiotics

Drug Profile

Research programme: antibacterials - Deinobiotics

Latest Information Update: 26 Mar 2013

Price : $50

At a glance

  • Originator Deinove
  • Developer CNRS; Deinove; Nosopharm
  • Class Bacteria
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Research Bacterial infections

Most Recent Events

  • 26 Mar 2013 Early research is ongoing in France
  • 15 Nov 2010 Early research in Bacterial infections in France (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top